Search academic texts

Information × Registration Number 0218U003362, 0115U000813 , R & D reports Title To improve the treatment of patients with non-Hodgkin diffuse large-B-lymphoma considering immunohistohimichnyh and molecular genetic markers popup.stage_title Head Kryachok Iryna, Registration Date 02-02-2018 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The purpose of the work is to determine the role of immunohistochemical and molecular genetic markers in the prognosis of the Nehhodzhkin diffuse In-large-cell lymphoma, to optimize the treatment of patients with non-Hodgkin's diffuse V-cell lymphomas using the latest chemotherapy regimens. The analysis of the predictive value of immunohistochemical and molecular genetic markers for the prognosis of the disease in 267 patients with DVKL has been carried out. There was no significant difference in the positive expression of markers such as Bcl-2, MUM1 and CD30 between groups of patients responding to first-line treatment and primary refractory patients (84.7% and 82.1%, 70.8%, and 60 , 0%, 23.3% and 25.0% respectively, p> 0.05 respectively). There was a tendency towards more frequent positive CD10 expression in the group that responded to treatment of the first line: 44.3% and 28.6% respectively, p> 0.05. Positive expression of Вcl-6 was significantly less frequent in the group of primary-refractory patients (67.6% and 36.4% respectively, p <0.05). IDO-positive expression is found to be an important marker associated with reduced progression-free survival (VLP) in patients with DVKKL. The 4-year ULP in the IDO-positive group was 50% compared with 73% in the IDO-negative group (p = 0.002). It was found that 1-year survival was 13%, 3-year-old by 12%, and 5-year-old by 11% higher in patients receiving chemo-radiation therapy compared with patients receiving chemotherapy alone (p = 0.02). The metabolic volume of the tumor (MTV), estimated at PET-CT before treatment, is an independent prognostic factor. The MTV value above 1155 ml is a prognostic disadvantage and is associated with frequent refractory and progressive disease progression, despite rituximab-containing therapy, the risk of progression increases (p = 0.005), VS = 1.4 (95% VI 1.1 -1, 7) for every 100 MTV growth units. The presence of c-myc expression and translocation t (8; 14) in patients with PMVKL is not related to survival (87.2% in the c-myc group versus 93.3% in the c-myc group + "(P0,05), which does not confirm their predictive significance. It was determined that among the biological factors for the DVTNL of the negative prediction group, the negative predictive value for the 2-year-old TBV and 2-year TB was expressed by the BCL-2 protein expression (P = 0.02 and P = 0.03, respectively). Indicators of direct and long-term treatment outcomes of the PDEBs of the adverse-prognosis group were the best in the group of patients receiving RT courses under the R-DA-EPOCH scheme. In this group, the highest rates of overall response to therapy (P = 0.047) and PR (P = 0.005) were recorded for such long-term treatment outcomes (P = 0.0096 for 2 years of BPV and P = 0.043 for 2 years of age). Conduction of FT patients with DVTNL of an unfavorable prognosis group improves the results of therapy in all groups). Product Description popup.authors Є. Кущевий А. Мартинчик К. Філоненко Крячок Ірина Анатоліївна О. Алексик Титоренко Ірина Борисівна Я. Степанішина popup.nrat_date 2020-04-02 Close